Skip to Content

Pacritinib Approval Status

  • FDA approved: No
  • Generic name: pacritinib
  • Company: CTI BioPharma Corp.
  • Treatment for: Myelofibrosis

Pacritinib is an investigational oral JAK2/FLT3 multikinase inhibitor in development for the treatment of patients with myelofibrosis.

Development Status and FDA Approval Process for pacritinib

DateArticle
Feb  9, 2016CTI BioPharma Provides Update on Clinical Hold of Investigational Agent Pacritinib and NDA
Jan  5, 2016CTI BioPharma and Baxalta Complete Submission of NDA for Pacritinib for Unmet Medical Need in Myelofibrosis
Nov 23, 2015CTI BioPharma Initiates Rolling Submission of NDA for Pacritinib for the Treatment of Patients with Myelofibrosis
Sep 23, 2015CTI BioPharma To Submit NDA For Pacritinib In Q4 Based Primarily On Data From Single Pivotal Persist-1 Trial

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide